



GENETICALLY  
ENGINEERED  
MODELS  
(GEM)



MICE  
Humanized

NATURAL  
IMMUNO-  
DEFICIENT

## B6 hGLP-1R Mouse

**Strain name:**

C57BL/6Smoc-*Glp1r*<sup>em2(hGLP1R)</sup>/SmocRj

**Type:** Humanized mouse, GMO

**Origin:** Shanghai Model Organism Center

**Colour and related genotype:**

Black mouse

WILD TYPE

NATURAL  
MUTANTS



### Presentation of the model

The hGLP-1R mouse is a genetically engineered knock-in (KI) model, homozygous for the human Glucagon-Like Peptide-1 Receptor (hGLP-1R), developed to support translational research in diabetes, obesity, and metabolic disorders, particularly for therapeutic modalities specifically targeting the human receptor.

The model carries a humanized GLP-1R allele, in which the murine *Glp1r* coding sequence is replaced by or functionally substituted with the human GLP-1R gene, while preserving physiological expression patterns.

The GLP-1 receptor is a key regulator of glucose homeostasis, insulin secretion, appetite control, and energy balance. While murine and human GLP-1R share significant homology, species-specific differences exist in receptor sequence, ligand affinity, signaling dynamics, and pharmacological responsiveness, which can limit the predictive value of standard mouse models when evaluating human-specific GLP-1-based therapies.

To address this limitation, the hGLP-1R mouse has been engineered to express the human GLP-1R, allowing:

- Accurate assessment of human-specific agonists, antagonists, antibodies, and biologics (Figure 3 and 4)
- Improved translational relevance for PK/PD and efficacy studies
- Reduced risk of species-related false negatives during preclinical development

Key characteristics:

- Homozygous expression of human GLP-1R under endogenous regulatory control
- Preservation of tissue-specific expression (pancreatic  $\beta$ -cells, CNS, gut, peripheral tissues)

The model remains otherwise fully immunocompetent.



### Main application and research fields

METABOLIC DISEASE

DIABETES RESEARCH

OBESITY PHARMACOLOGY

INCRETIN BIOLOGY

DRUG DISCOVERY



### Our added value

- The «JANVIER LABS Genetic Policy», specific programme, guarantees homozygosity of autosomal pairs
- Animals with the SPF or SOPF standards
- A gentling policy for docile and easy-to-handle animals
- Optimal stability conditions of our models during shipments, thanks to our dedicated and internal transport service
- A scientific support with a team of Veterinarians and PhD



contact@janvier-labs.com  
Tel +33 (0)2 43 02 11 91  
[www.janvier-labs.com](http://www.janvier-labs.com)



## Validation data:

Parameter	Units	C57BL6 F WT	C57BL6 M WT	C57BL6 hGLP1R F	C57BL6 hGLP1R M
WBC	(10 <sup>3</sup> /uL)	9.8±0.63	9.41±0.23	10.37±0.24	9.58±0.43
RBC	(10 <sup>6</sup> /uL)	10.97±0.08	10.39±0.21	9.43±0.27	9.18±0.25
HGB	(g/dL)	16.77±0.2	15.87±0.33	14.27±0.36	14.2±0.46
HCT	(%)	52.13±0.32	51.1±0.92	49.43±0.95	48.3±0.9
MCV	(fL)	47.5±0.17	49.1±0.36	52.6±0.17	52.67±0.41
MCH	(pg)	15.3±0.1	15.27±0.02	15.38±0.18	15.43±0.25
MCHC	(g/dL)	32.17±0.19	31.03±0.08	28.87±0.48	29.37±0.41
PLT	(10 <sup>3</sup> /uL)	1330.33±30.74	1649.67±76.12	1512±74.13	1807±57.73
RDW-SD	(fL)	28.43±0.1	30.97±0.2	36.77±1.85	33.2±1.13
RDW-CV	(%)	21.07±0.1	21.13±0.2	22.13±0.42	20.6±0.18
PDW	(fL)	7.4±0.03	7.5±0.09	7.23±0.18	6.97±0.1
MPV	(fL)	6.67±0.05	6.77±0.02	6.63±0.13	6.37±0.04
P-LCR	(%)	4.37±0.19	5.23±0.13	4.73±0.59	3.57±0.17
PCT	(%)	0.89±0.02	1.12±0.05	0.99±0.03	1.15±0.04
NEUT#	(10 <sup>3</sup> /uL)	0.85±0.07	1.6±0.22	0.45±0.02	0.47±0.03
LYMPH#	(10 <sup>3</sup> /uL)	8.3±0.57	7.07±0.08	9.47±0.23	8.67±0.42
MONO#	(10 <sup>3</sup> /uL)	0.41±0.02	0.62±0.07	0.28±0.01	0.31±0.02
EO#	(10 <sup>3</sup> /uL)	0.24±0.02	0.12±0.01	0.16±0.01	0.12±0.0
BASO#	(10 <sup>3</sup> /uL)	0.01±0.0	0±0	0.01±0.0	0.01±0.0
NEUT	(%)	8.6±0.41	16.7±2.05	4.37±0.08	4.97±0.39
LYMPH	(%)	84.57±0.59	75.43±2.52	91.33±0.11	90.43±0.41
MONO	(%)	4.33±0.54	6.5±0.64	2.67±0.14	3.23±0.25
EO	(%)	2.43±0.1	1.33±0.17	1.57±0.17	1.3±0.09
BASO	(%)	0.07±0.02	0.03±0.02	0.07±0.02	0.07±0.02



Table 1. Hematological parameters comparing C57BL6 wild-type mice to C57BL6 hGLP1R mice (Data are presented as mean and ± SEM).

Parameter	Units	C57BL6 F WT	C57BL6 M WT	C57BL6 hGLP1R F	C57BL6 hGLP1R M
ALT	(U/L)	28.67±0.96	38.67±1.07	24.67±0.69	26.67±0.51
AST	(U/L)	56±1.2	62.67±0.96	54.67±0.38	54.33±1.26
UREA	(mmol/L)	11.23±0.47	11.27±0.68	9.53±0.08	10.73±0.25
CRE	(µmol/L)	13.49±0.51	8.4±0.08	14.85±0.23	15.67±0.08
HDL-C	(mmol/L)	1.67±0.01	1.84±0.04	1.78±0.05	2.03±0.02
LDL-C	(mmol/L)	0.56±0.01	0.44±0	0.57±0.01	0.46±0.01
TCHO	(mmol/L)	2.25±0.01	2.58±0.05	2.49±0.04	2.76±0.02
TG	(mmol/L)	0.9±0.04	1.55±0.05	1.27±0.07	1.67±0.05
UA	(µmol/L)	148.93±2.59	117.9±3.15	114.3±5.05	105.93±1.93



Table 2. Biochemical blood parameters comparing C57BL6 wild-type mice to C57BL6 hGLP1R mice (Data are presented as mean and ± SEM).



## Validation data:




Fig 1. Detection of GLP1R and Gapdh expression in lung, heart, brain, stomach, salivary gland, duodenum and small intestine by RT-PCR.




Fig 2. Detection of human GLP-1R expression in hGLP-1R mice by IHC. Pancreas, salivary gland, colon, heart, lung, brain, stomach and duodenum were collected from homozygous hGLP-1R mice (HO/HO), and analyzed by IHC with anti-human GLP-1R antibody. Human GLP-1R is specifically expressed in islets of the pancreas.



## Validation data:




Fig 3. Validation of the hypoglycemic efficacy of the test compound in humanized GLP-1R mice. The oral glucose tolerance test (OGTT) was performed (n=5), and the test compound showed a better hypoglycemic efficacy ( $p < 0.001$ ). The above data indicated that the GLP-1R humanized mouse is an effective model for diabetes drug screening.

### OGTT results of different groups




Fig 4. Efficacy study of PF06882961 in hGLP1R mice. PF06882961 has shown significant effect in hGLP1R mice in OGTT study, but no effect in C57BL/6 mice.